The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
Abstract
OBJECTIVE: Abacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue reverse transcriptase inhibitor, causes severe hypersensitivity in 4-8% of patients. HLA B*5701 is a known genetic risk factor for abacavir hypersensitivity in Caucasians. Our aim was to confirm the presence of this genetic factor in our patients, and to determine whether genotyping for HLA B*5701 would be a cost-effective use of healthcare resources. METHODS: Patients with and without abacavir hypersensitivity were identified from a UK HIV clinic. Patients were genotyped for HLA B*5701, and pooled data used for calculation of test characteristics. The cost-effectiveness analysis incorporated the cost of testing, cost of treating abacavir hypersensitivity, and the cost and selection of alternative antiretroviral regimens. A probabilistic decision analytic model (comparing testing versus no testing) was formulated and Monte Carlo simulations performed. RESULTS: Of the abacavir hypersensitive patients, six (46%) were HLA B*5701 positive, compared to five (10%) of the non-hypersensitive patients (odds ratio 7.9 [95% confidence intervals 1.5-41.4], P = 0.006). Pooling of our data on HLA B*5701 with published data resulted in a pooled odds ratio of 29 (95% CI 6.4-132.3; P < 0.0001). The cost-effectiveness model demonstrated that depending on the choice of comparator, routine testing for HLA B*5701 ranged from being a dominant strategy (less expensive and more beneficial than not testing) to an incremental cost-effectiveness ratio (versus no testing) of Euro 22,811 per hypersensitivity reaction avoided. CONCLUSIONS: Abacavir hypersensitivity is associated with HLA B*5701, and pre-prescription pharmacogenetic testing for this appears to be a cost-effective use of healthcare resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Searching for genetic determinants in the new millennium
Risch, N. J. (2000) · Nature · doi:10.1038/35015718 · Cited by 1,839
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Representing uncertainty: the role of cost‐effectiveness acceptability curves
Fenwick, E., Claxton, K., & Sculpher, M. (2001) · Health Economics · doi:10.1002/hec.635 · Cited by 1,110
Bunce, M., O'Neill, C. M., Barnardo, M. C. N. M., Krausa, P., Browning, M. J., Morris, P. J., & Welsh, K. I. (1995) · Tissue Antigens · doi:10.1111/j.1399-0039.1995.tb03127.x · Cited by 997
Pharmacogenetics and the practice of medicine
Roses, A. D. (2000) · Nature · doi:10.1038/35015728 · Cited by 810
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Lafon, S., Pearce, G., & Steel, H. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80132-6 · Cited by 406
Genetic susceptibility to adverse drug reactions
Pirmohamed, M., & Park, B. K. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01717-x · Cited by 328
Self-citationMartínez, E., Arnaiz, J. A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., Knobel, H., Riera, M., Pedrol, E., Force, L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021589 · Cited by 291
Cited by
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperavičiūtė, D., Carrington, M., Sills, G. J., Marson, T., Jia, X., de Bakker, P. I. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013297 · Cited by 925
Self-citationLeckband, S. G., Kelsoe, J. R., Dunnenberger, H. M., George, A. L., Tran, E., Berger, R., Müller, D. J., Whirl-Carrillo, M., Caudle, K. E., & Pirmohamed, M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.103 · Cited by 335
Self-citationChessman, D., Kostenko, L., Lethborg, T., Purcell, A. W., Williamson, N. A., Chen, Z., Kjer-Nielsen, L., Mifsud, N. A., Tait, B. D., Holdsworth, R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.020 · Cited by 334
HLA-B Locus in Caucasian Patients with Carbamazepine hypersensitivity
Alfirevic, A., Jorgensen, A. L., Williamson, P. R., Chadwick, D. W., Park, B. K., & Pirmohamed, M. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.813 · Cited by 264
Self-citation
Metadata
- Authors
- Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K., & Pirmohamed, M.
- Venue
- Pharmacogenetics
- Published
- 2004-06
- Volume
- 14
- Issue
- 6
- Pages
- 335-342
- ISSN
- 0960-314X (ISSN-L)
- OpenAlex
- W2082126453
- Cited by
- 290
- References
- 21
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. https://app.cochat.ai/papers/10.1097/00008571-200406000-00002
- The paper
- Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K., & Pirmohamed, M. (2004). Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. https://doi.org/10.1097/00008571-200406000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.